coronavirus vaccine
Covid vaccine: UNICEF emphasises speed, simplicity to remove barriers
UNICEF Executive Director Henrietta Fore has said they need speed and simplicity to remove barriers to the acquisition, manufacture and distribution of COVID-19 vaccines globally.
“The COVID-19 pandemic has made clear to us all that no one is safe until everyone is safe. But equitable access to COVID-19 vaccines is within our grasp," She said in a statement on Tuesday.
She said they have proven that the world can rally to do the unthinkable, and we need to do it again. "The sooner we do, the sooner our lives, and the lives of our children, will go back to normal.”
In a little over a year, the world’s scientists, businesses, governments, philanthropists and multilateral institutions rallied and did the unthinkable, Fore said.
They created vaccines to fight a virus that had brought the world to a standstill. And they tested, transported and began to administer those vaccines safely and in record time. "This is nothing short of astounding," she said.
“But the fight is not yet over,” Fore said. “Variants are emerging all over the world, and with each, the risk of a massive global setback."
Also read: Vaccine passports are latest flash point in COVID politics
At the current rate, there is simply not enough vaccine supply to meet demand. And the supply available is concentrated in the hands of too few.
Some countries have contracted enough doses to vaccinate their populations several times, while other countries have yet to receive even their first dose.
"This threatens us all. The virus and its mutations will win," Fore said.
In order to get ahead of the virus, and to shift gears, she said, they must build on a strategy of vaccinating frontline workers but drive towards a strategy that truly enables equitable access for all.
The governments, businesses and partners were urged to take three urgent actions:
First, simplify Intellectual Property Rights (IPR) through voluntary and proactive licensing by IPR holders.
Also read: UNICEF launches COVID-19 vaccine market dashboard to ensure fair access
But this alone won’t increase production. Unlike drug manufacture, vaccine production involves a complex manufacturing process with multiple components and steps.
IPR holders would need to provide technology partnerships to accompany IP licenses, proactively share know-how and sub-contract to manufacturers without undue geographic or volume restrictions.
This challenge requires not forced IP waivers but proactive partnership and cooperation. Recent manufacturing partnerships such as Pfizer-BioNtech; AZ-SII, J&J- Merck and J&J-Aspen are encouraging examples.
UNICEF urged others to follow suit, to increase the scale and geographic diversity of manufacturing capacity.
“While markets alone can’t guarantee innovation benefits all, voluntary licensing, pooled funds and multilateral mechanisms such as COVAX are an effective and realistic way for product developers and manufacturers to collaborate, innovate, and encourage equitable access," Fore said.
“Second, we need to end vaccine nationalism. Governments should remove direct and indirect export- and import-control measures that block, restrict or slow down exports of COVID-19 vaccines, ingredients and supplies. Viruses respect no borders. Defeating COVID-19 in each of our home countries also means defeating it around the world by ensuring a steady flow of vaccines and supplies to all."
Also read: UNICEF working with over 350 partners to deliver COVID-19 vaccines
Finally, Fore said, governments that have contracted to receive more ‘future doses’ than required to vaccinate their entire adult populations this year, should immediately loan, release or donate most or all excess contracted doses for 2021 to COVAX, so they can be allocated equitably among other countries.
“In addition, countries with a sufficient, current supply of manufactured doses should consider donating at least 5% of their available manufactured doses right away, and commit to making further contributions on a continued, rolling basis throughout the year, scaling up their contributions in line with rising supply. Confirming these dose-sharing commitments now will enhance predictability, accelerate equitable access, and help stabilise the global vaccine market."
Fully vaccinated people can travel safely again, CDC says
Add travel to the activities vaccinated Americans can safely enjoy again, according to new U.S. guidance issued Friday.
The Centers for Disease Control and Prevention updated its guidance to say fully vaccinated people can travel within the U.S. without getting tested for the coronavirus or going into quarantine afterward.
Still, CDC Director Dr. Rochelle Walensky urged caution and said she would “advocate against general travel overall" given the rising number of infections.
“If you are vaccinated, it is lower risk,” she said.
According to the CDC, nearly 100 million people in the U.S. — or about 30% of the population — have received at least one dose of a COVID-19 vaccine. A person is considered fully vaccinated two weeks after receiving the last required dose.
Also read: Fully-vaccinated people can gather without masks: CDC
The agency had said it would update its guidance as more people got vaccinated and evidence mounted about the protection the shots provide.
“Every day you get more data, and you change your guidance," said Dr. Ali Khan, dean of the University of Nebraska's College of Public Health.
The CDC is sticking to its guidance for unvaccinated people to avoid unnecessary travel. If they do travel, the agency says to get tested one to three days before the trip, and three to five days after. People should also stay home and quarantine for seven days after travel, even if their COVID-19 test is negative, the agency says.
The new guidance says:
— Fully vaccinated people can travel within the U.S., without getting tested for the coronavirus or quarantining. People should still wear a mask, socially distance and avoid crowds, the agency says.
— For international travel, the agency says vaccinated people do not need to get a COVID-19 test before leaving, unless the destination country requires it.
— For travelers coming into the U.S., vaccinated people should still get a negative COVID-19 test before boarding a flight, and be tested three to five days after arrival. They do not need to quarantine. The agency noted the potential introduction of virus variants and differences in vaccine coverage around the world for the cautious guidance on overseas travel.
Also read: CDC: Strong evidence in-person schooling can be done safely
Already, air travel in the United States has been picking back up. Although traffic remains down by nearly half from a year ago, more than 1 million travelers daily have been going through U.S. airports in recent weeks.
Airlines do not require COVID-19 tests or proof of vaccination for travel in the U.S.
The CDC cited recent research on the real-world effects of the vaccines for its updated guidance. Last month, the agency said fully vaccinated people could visit with each other indoors without wearing masks or social distancing. It also said vaccinated people could visit with unvaccinated people from a single household under similar conditions, as long as the unvaccinated individuals were at low risk for severe illness if infected.
The U.S. began its vaccine rollout in mid-December. Vaccines from Pfizer and Moderna require two doses given a few weeks apart. A one-shot vaccine by Johnson & Johnson was given the green light by regulators at the end of February.
Company at heart of J&J vaccine woes has series of citations
The company at the center of quality problems that led Johnson & Johnson to discard an unknown amount of its coronavirus vaccine has a string of citations from U.S. health officials for quality control problems.
Emergent BioSolutons, a little-known company at the center of the vaccine supply chain, was a key to Johnson & Johnson’s plan to deliver 100 million doses of its vaccine to the U.S. by the end of May. But the company has been cited repeatedly by the Food and Drug Administration for problems such as poorly trained employees, cracked vials and mold around one of its facilities, according to records obtained by The Associated Press through the Freedom of Information Act. The records cover inspections at Emergent facilities since 2017.
Johnson & Johnson said Wednesday that a batch of vaccine made by Emergent at its Baltimore factory, known as Bayview, can’t be used because it didn’t meet quality standards. It wasn’t clear exactly how many doses were involved or how the problem would affect future delivers of J&J’s vaccine. The company said in a statement it was still planning to deliver 100 million doses by the end of June and was “aiming to deliver those doses by the end of May.”
J&J locked arms with Emergent in April 2020, enlisting the lesser-known company to manufacture the vaccine J&J was developing with federal funding. At the time, Emergent’s Bayview facility wasn’t scaled for making millions of doses of a potential COVID-19 vaccine, according to the FDA records that describe the plant as a contract testing laboratory that “did not manufacture products for distribution.” Upgrades in technology and personnel were required before Bayview could begin making what’s known as “drug substance” material for the vaccine, a two-month process during which the required biological cells are grown.
Also read: EU regulator approves J&J’s one-shot COVID-19 vaccine
The FDA inspected Emergent’s Bayview plant in April 2020, just as the agreement with J&J was being announced. The federal agency criticized the company for problems with its testing of a potential treatment for anthrax, according to the records obtained by the AP. The FDA’s lead investigator cited the company for failing to train employees “in the particular operations they perform as part of their function and current good manufacturing practices.”
On the same day, Johnson & Johnson, in a separate news release, heralded its partnership with Emergent as a step toward the pharmaceutical giant’s goal of supplying more than 1 billion doses of the vaccine globally by the end of 2021.
Other problems cited by the FDA during the April 2020 inspection included failures by the Bayview plant “to ensure that electronically held data generated during analytical testing” of material “was protected from deletion or manipulation.” The FDA’s lead investigator, Marcellinus Dordunoo, wrote that Emergent hadn’t investigated what he described as “data integrity concerns.”
The inspection was the most recent in a series of critical reports from the FDA about Emergent, including one following a December 2017 inspection at a plant in Canton, Massachusetts, in which the FDA said the company hadn’t corrected “continued low level mold and yeast isolates” found in the facility. Nearly a year later, agency investigators questioned why Emergent had “an unwritten policy of not conducting routine compliance audits” at a separate plant in Baltimore, known as Camden, where an anthrax vaccine is filled into vials.
Also read: Merck to help produce rival J&J’s COVID-19 vaccine
Emergent’s revenues skyrocketed during the Trump administration, jumping from around $523 million in 2015 to more than $1.5 billion in 2020. The company has invested heavily in lobbying the federal government, according to disclosure records, which show the company spent $3.6 million on lobbying in 2020 alone.
Emergent is one of about 10 companies that Johnson & Johnson is using to speed up manufacturing of its recently approved vaccine, the company said. The Bayview factory where the tainted vaccine ingredient was found had not yet been approved by the FDA, so no vaccine in circulation is affected. Emergent declined to comment.
President Joe Biden has pledged to have enough vaccines for all U.S. adults by the end of May. The U.S. government has ordered enough two-dose shots from Pfizer and Moderna to vaccinate 200 million people to be delivered by late May, plus the 100 million single-dose shots from J&J.
A federal official said Wednesday evening the administration’s goal can be met without additional J&J doses.
A J&J spokesman said earlier Wednesday that the company met the end-of-March goal, and the Centers for Disease Control and Prevention’s online vaccine tracker showed J&J had provided about 6.8 million doses to the U.S. vaccine effort. J&J has been shipping finished vaccines from its factory in the Netherlands to the U.S.
Also read: FDA says single-dose shot from J&J prevents severe COVID
J&J said it was putting more of its manufacturing and quality experts inside Emergent’s factory to supervise production of the COVID-19 vaccine, a move meant to enable delivery of an additional 24 million vaccine doses through April.
J&J said it still expects to deliver more than 1 billion vaccine doses globally by the end of the year.
The J&J vaccine has been viewed as crucial for vaccination campaigns around the world, because only one shot is required and it can be shipped and stored at standard refrigeration temperatures, unlike some other vials that must be kept frozen. The company also has pledged to sell the vaccine without a profit, but only during the pandemic emergency.
The problem with the vaccine batch was first reported by The New York Times. The FDA said it was aware of the situation but declined further comment.
No uncertainty over receiving vaccine doses: Finance Minister
Finance Minister AHM Mustafa Kamal has ruled out any uncertainty over receiving vaccine doses from the Serum Institute of India Pvt Ltd.
“We’ve already paid for the vaccine. So... we’ll get it,” he told reporters while briefing virtually on the Cabinet Committee on Public Purchase on Wednesday.
Also read: Vaccine drive to continue with AstraZeneca shot: Health Secretary
He informed that the second dose of vaccine will be administered in time.
He also said that the health minister had also attended the purchase body meeting and did not express any apprehension over uncertainty about receiving the vaccine doses.
Also read: Virus variants, vaccine inequity responsible for rising Covid caseload: WHO
Mustafa Kamal also turned down the idea of going for lockdown to contain coronavirus transmission. He said there will be no need for any such measures as the vaccination programme has been continuing.
“Once vaccination is completed, the situation will improve,” he said. “The countries, which are running the vaccination programme, are witnessing a fall in infection.”
Also read: Modi to bring 12 lakh more vaccine doses as gift for Bangladesh
Responding to a question on World Bank’s economic growth projection at 3.6 percent, the Finance Minister said the donor agency makes such projection on quarterly basis and the government does it annually.
Trash scavengers who help keep cities clean plea for vaccine
The scavengers wait patiently for a dump truck to tip the trash on the summit of the landfill outside New Delhi. Armed with plastic bags, they plunge their bare hands into the garbage and start sorting it.
Every day, more than 2,300 tons of garbage is dumped at the landfill at Bhalswa that covers an area bigger than 50 football fields, with a pile taller than a 17-story building. And every day, thousands of these informal workers climb the precarious slopes to pick through what can be salvaged.
They are among the estimated 20 million people around the world — in rich nations and poor — who are pivotal in keeping cities clean, alongside paid sanitation employees. But unlike those municipal workers, they usually are not eligible for the coronavirus vaccine and are finding it hard to get the shots.
Also read: Virus variants, vaccine inequity responsible for rising Covid caseload: WHO
The pandemic has amplified the risks that these informal workers face. Few have their own protective gear or even clean water to wash their hands, said Chitra Mukherjee of Chintan, a nonprofit environmental research group in New Delhi.
“If they are not vaccinated, then the cities will suffer,” Mukherjee said.
Manuwara Begun, 46, lives in a cardboard hut behind a five-star hotel in the heart of New Delhi and feels the inequity keenly. Chintan estimates that each year, those like her save the local government over $50 million and eliminate over 900,000 tons of carbon dioxide by diverting waste away from landfills.
Still, they are they not considered “essential workers” and thus are ineligible for vaccinations.
Begun has started an online petition pleading for vaccines and asking, “Are we not human?”
Sanitation workers employed by local governments in South Africa and Zimbabwe are likely to be in line for the COVID-19 vaccine after health workers, unlike those who sort through the trash. At the Dandora landfill in Kenya’s capital of Nairobi, some of the scavengers who are not eligible for a shot wear medical gear discarded by hospitals and health clinics, saying it especially protects them from the weather during the rainy season.
There is no doubt that these people provide an essential service, says Louise Guibrunet, a researcher at National Autonomous University of Mexico who has studied the issue.
Also read: Leaders of "Quad" agree to aid vaccine delivery to developing nations
In Mexico, scavengers help municipal workers on garbage trucks and often collect trash from neighborhoods not served by authorities. The work is dangerous, and injuries are common, so governments have an incentive to not recognize them or provide benefits like health care, she said.
They often are already poor, moving to unfamiliar cities to eke out a living by sorting garbage, says Robin Jeffrey, a professor at the Institute of South Asian Studies at the National University of Singapore. That many of these workers in India belong to poor Muslim or Dalit communities, who once were known as “untouchables” at the bottom of the country's caste system, adds a layer of prejudice.
“The vaccine is just another, and very dramatic, example of an exclusion that has prevailed before COVID-19 came on the horizon,” said Jeffrey, who co-authored a book on waste in India in 2018.
India said it will give vaccines to everyone over 45 starting April 1. At private hospitals, each shot is sold for 250 rupees ($3.45), but they are free at government hospitals.
Because the pandemic sent the price of oil crashing, it became cheaper to make new plastic than to recycle it. In many countries, closed borders brought recycling markets to a halt, lowering demand for reused materials that the workers collect.
In New Delhi, a pound of plastic bottles sells for the equivalent of 11 U.S. cents, half of what it brought before the pandemic. Sahra Bano, 37, who lives near the Bhalswa landfill and sells what she can scavenge, says she used to earn about 400 rupees ($5) per day. Now, getting even half that is difficult.
Toxic runoff from the landfill infiltrates the groundwater, so she must spend 40 rupees (5 cents) per day on bottled water; the rest of what she earns goes for food. To earn enough to get one shot of the vaccine, she said she would have to collect and sell an additional 31 pounds of plastic bottles.
“We are struggling to feed our family. How can we buy vaccines?” she asks.
Also read: UN launches ‘Only Together’ campaign to support global vaccine equity call
To get the free vaccine from an overburdened public hospital, she would have to wait there for days, and each day away from work is one without food on the table. Moreover, the stigma associated with waste workers in India means they are often turned away from such facilities.
“They don’t treat us well,” Bano says.
Any illness means visiting a drugstore, not a doctor, for medicine.
If they’re lucky, the person recovers, she says, adding: “If not, what can we do?”
Canada pauses AstraZeneca vaccine for under 55
Canada on Monday suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 following concerns it might be linked to rare blood clots.
The National Advisory Committee on Immunization had recommended the pause for safety reasons and the Canadian provinces, which administer health in the country, announced the suspension Monday.
“There is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks,” said Dr. Shelley Deeks, vice chair of the National Advisory Committee on Immunization.
Also read: AstraZeneca: US data shows vaccine effective for all adults
Deeks said the updated recommendations come amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000, much higher than the one in one million risk believed before.
She said most of the patients in Europe who developed a rare blood clot after vaccination with AstraZeneca were women under age 55, and the fatality rate among those who develop clots is as high as 40%.
Dr. Joss Reimer of Manitoba’s Vaccine Implementation Task Force said despite the finding that there was no increase risk of blood clots overall related to AstraZeneca in Europe, a rare but very serious side effect has been seen primarily in young women in Europe.
Reimer said the rare type of blood clot typically happens between four and 20 days after getting the shot and the symptoms can mirror a stroke or a heart attack.
“While we still believe the benefits for all ages outweigh the risks I’m not comfortable with probably. I want to see more data coming out of Europe so I know exactly what this risk benefit analysis is,” Reimer said.
The AstraZeneca shot, which has been authorized in more than 70 countries, is a pillar of a U.N.-backed project known as COVAX that aims to get COVID-19 vaccines to poorer countries. It has also become a key tool in European countries’ efforts to boost their sluggish vaccine rollouts. That makes doubts about the shots especially worrying.
Also read: AstraZeneca confirms strong vaccine protection after US rift
“This vaccine has had all the ups and downs. It looks like a roller coaster,” said Dr. Caroline Quach-Thanh, the chair of the National Advisory Committee on Immunization, when asked if the latest news will lead to further vaccine hesitancy.
Health Canada said it has not received any reports of blood clots in Canada, and the department’s chief medical adviser, Dr. Supriya Sharma, said she still believes the vaccine’s benefits outweigh the risks.
Last week, the department changed its label on the vaccine to warn about the rare risk of blood clots.
Only those 60 and above have received AstraZeneca in Ontario, Canada's most populous province.
“We have no concerns with those who have received it so far,” said Dr. David Williams, Ontario's chief medical officer.
Mark Mendelson, a 63-year-old Toronto man who has had heart surgery, said that he has no regrets about getting his first AstraZeneca dose two weeks ago and that he will get the second.
“Get what you can,” Mendelson said. “I had no ill effects at all from the AstraZeneca. I am in a better position than those who don’t have any vaccine at all. If you are betting person you would take those odds any day of the week. I’m quite prepared to roll the dice.”
Several European countries that had suspended using the vaccine over concerns it could cause blood clots have resumed administering it after the EU’s drug regulator said the vaccine was safe.
The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then more recently the scare about clots that had some countries temporarily pausing inoculations.
Canada is expected to receive 1.5 million doses of AstraZeneca from the U.S. on Wednesday.
“The messaging has been brutal overall. I am fearful it is toast. It shouldn't be," said Dr. Andrew Morris, a professor of infectious diseases at the University of Toronto and the medical director of the Antimicrobial Stewardship Program at Sinai-University Health Network.
Morris thinks those who are at a high risk for a bad COVID-19 outcome and over the age of 55 should get AstraZeneca if the other vaccines are not available to them, especially during a third wave of coronavirus infections.
Canadian regulators approved the Pfizer, Moderna, AstraZeneca and Johnson & Johnson vaccines. Canada has placed bigger bets on Pfizer and Moderna, ordering up to 76 million doses of Pfizer and up to 44 million of Moderna, compared with up to 20 million of AstraZeneca. It's not known when Canada will receive its first shipment of Johnson & Johnson.
Canada received its first shipment of AstraZeneca this month — 500,000 doses from India. Of the 194,500 doses that Ontario received, about 10,000 remain. They expire April 2.
Also read: AstraZeneca vaccinations resume in Europe after clot scare
Canada has lagged on vaccinating its population because it lacks the ability to manufacture the vaccine and has had to rely on the global supply chain for the lifesaving shots, like many other countries.
With no domestic supply, Prime Minister Justin Trudeau’s government bet on seven different vaccines manufactured elsewhere and secured advance purchase agreements — enough to get 10 doses for each of Canada’s 38 million people. While acquiring them has proven difficult, deliveries have ramped up this month. Canada expects to have more than 36.5 million doses by July and officials hope to get at least one dose into all adults who want one by the end of June.
The National Advisory Committee on Immunization earlier recommended a four-month delay between doses after data from the U.K. and Quebec showed a good level of protection offered by the first shot. The U.K. has instituted a similar delay.
India will always stand by Bangladesh: Modi
Indian Prime Minister Narendra Modi on Saturday said India will always stand by the progress and development of Bangladesh as a faithful friend.
He said this when he paid a courtesy call on President Abdul Hamid at Bangabhaban in the evening.
Modi said Bangladesh has always been considered a trusted friend of India.
Also read: Ground-level cooperation needed to check all border incidents: Modi
He also lauded the continuous socio-economic development of Bangladesh under Prime Minister Sheikh Hasina, President's Press Secretary Md Joynal Abedin told UNB after the meeting.
President Hamid welcomed the Indian Prime Minister at Bangabhaban and thanked him for attending the birth centenary of Father of the Nation Bangabandhu Sheikh Mujibur Rahman and the golden jubilee of Bangladesh's independence.
He said Modi’s visit would be a unique milestone in strengthening the existing diplomatic ties between the two neighbouring countries.
Also read: Bangladesh, India for progress of whole world: Modi
During the meeting, President Hamid expressed sincere thanks to the Government of India for conferring the ‘Gandhi Peace Prize 2020’ on Bangabandhu posthumously in recognition of his outstanding contributions towards social, economic and political transformation through non-violent and other Gandhian methods.
The President also thanked the Government of India for sending Coronavirus vaccine doses to Bangladesh as gift. He hoped that vaccine doses would come to Bangladesh from India on a commercial basis would also arrive in time.
Referring to India's support in 1971, the President thanked the Government and people of India for their support and cooperation in the Great War of Liberation.
Also read: Dhaka-Delhi to accelerate momentum; eye next 50 years diversified ties
The Indian PM also signed the visitors' book at Bangabhaban.
Bangladesh Foreign Minister Dr AK Momen, Agriculture Minister Dr Muhammad Abdur Razzaque, Indian National Security Adviser Ajit Doval, Indian Foreign Secretary Harsh Vardhan Shringla, among others, were present there.
India needs to play leading role in building stable, vibrant S Asia: PM Hasina
Prime Minister Sheikh Hasina on Friday said India, the largest country in the region, needs to play a pioneering role in building a stable and politically-economically vibrant South Asia.
“If we move forward hand in hand, the development of our people is inevitable,” she said while chairing the closing ceremony of the 10-day festival in presence of her Indian counterpart Narendra Modi as the guest of honour.
President Abdul Hamid attended the concluding ceremony in the city’s National Parade Square as the Chief Guest.
The 10-day nationwide programme started on March 17 with the theme ‘Mujib Eternal’, marking the birth centenary of Father of the Nation Bangabandhu Sheikh Mujibur Rahman and Golden Jubilee of the country’s Independence in the Mujib Year.
Sheikh Hasina said South Asia is the most densely-populated area but there are huge resources in this region. “If we all utilise the resources, we’ll be able to build it as a hunger-poverty-free region,” she noted.
She urged all to make a vow to work together forgetting all differences for the welfare of the peoples in South Asia.
“At this auspicious moment of celebrating the birth centenary of the Father of the Nation and the Golden Jubilee of independence of Bangladesh, let us pledge to forget all differences and work together for the welfare of our peoples,” she said.
“Our foreign policy formulated by the Father of the Nation is that ‘Friendship to All and Malice towards None’. We’re determined to establish South Asia a developed and prosperous region,” the Prime Minister said.
Relations with India reaches new heights
Sheikh Hasina said the bilateral relations between Bangladesh and India have escalated to new heights. “Our relations with India have now escalated to new heights,” she added.
Lauding Narendra Modi’s ‘neighbourhood first’ policy, she said, “He sent coronavirus vaccines as gift to the neighbouring countries, including Bangladesh, which was a reflection of that policy of Modiji.”
She said Bangladesh has increased cooperation with India in various sectors including trade and commerce, communication, power, energy, and agriculture during the last few years. “India has now become one of our development partners,” she added.
The Maitree Bridge over Feni River has recently been inaugurated to increase connectivity between the North-Eastern Indian states and Bangladesh. These Indian states are now able to use the Seaport and Airport of Chattogram, she said adding that India can also use the Mongla port.
Hasina said Bangladesh has graduated from the status of least developed country to a developing country due to her government’s relentless efforts in the last 12 years. “We’re taking Bangladesh on the track of prosperity by overcoming multiple obstacles,” she added.
Also read: Independence Day: PM Hasina pays homage to Bangabandhu
She said her government wants to make Bangladesh an upper-middle-income country by 2031 and a developed and prosperous one by 2041.
Sheikh Hasina, Bangabandhu’s eldest daughter, said Bangabandhu was a great believer in regional cooperation. “In addition to the political freedom of the oppressed people of the world, he dreamed of economic emancipation. That made him emphasise regional cooperation based on mutual trust, confidence, and equality,” she added.
She expressed gratitude to the Indian government and the Prime Minister for awarding the prestigious ‘Gandhi Peace Prize-2020’ to Bangabandhu at this very auspicious moment.
“I must say, India indeed honoured a worthy leader in South Asia as well as a real fellow of Gandhiji through this award,” she said.
She also thanked the government and the people of India as India is providing 109 ambulances to Bangladesh this time as a gift of their amicable gesture for the people of Bangladesh.
Noting that Indian government always remains beside Bangladesh, she said every Indian political party and the people of India, irrespective of their creed and views, become united regarding any issue of Bangladesh and stand beside the people of Bangladesh.
“India is not only our next-door neighbour, we’ve historical, social, cultural, heritage, and geographical rapports with this country,” she said.
Recollecting that the people and the Government of India were immensely involved in the evolution process of Bangladesh, Sheikh Hasina said, “The self-sacrifice (of a notable number of Indian soldiers), support, and cooperation of the people of India during our Liberation War will never be forgotten. We gratefully recollect that contribution.”
In recognition of outstanding contribution to the Liberation War, Bangladesh dedicated the ‘Independence Award’ to late Indian Prime Minister Indira Gandhi, the ‘Liberation War Friendship Award’ to 225 Indian citizens including the ‘Liberation War Award’ to former President Pranab Mukherjee and former Prime Minister Atal Bihari Vajpayee, she said.
On the occasion of the birth centenary of Father of the Nation, the Golden Jubilee of Bangladesh’s Independence, and 50 years of Bangladesh-India diplomatic relations, the two countries have decided to hold several joint programmes, she said.
Besides, the Indian government has taken the initiative of the Bangabandhu-Bapu Digital Exhibition commemorating the two most-reputed leaders of this subcontinent Bangabandhu Sheikh Mujib and Mahatma Gandhi, she continued.
Sheikh Hasina extended her sincere thanks to the Indian Prime Minister for attending this festival amid the Covid-19 pandemic. “We always recall with respect the contribution of India to our liberation. So, Indian Prime Minister Narendra Modi glorified our event attending it as the guest of honour,” she said.
At the event, Bangabandhu’s youngest daughter Sheikh Rehana accompanied by Sheikh Hasina received the prestigious ‘Gandhi Peace Prize-2020’ from Narendra Modi, which was conferred on Bangabandhu.
The Indian Prime Minister was honoured with ‘Eternal Mujib Memento’. Sheikh Rehana handed over the memento to Modi.
The video messages of UN Secretary General António Guterres and UK Prime Minister Boris Johnson were also screened.
Congratulatory messages from Pakistan Prime Minister Imran Khan, Russian President Vladimir Putin, USA President Joe Biden and Turkey President Recep Tayyip Erdoğan read out by the heads of their respective diplomatic missions stationed in Dhaka.
Earlier, Sheikh Hasina along with her younger sister Sheikh Hasina received Modi when he reached the venue at 4:30pm. Later, both the prime ministers witnessed a cultural programme there.
AstraZeneca vaccinations resume in Europe after clot scare
Countries across Europe resumed vaccinations with the AstraZeneca shot on Friday, as leaders sought to reassure their populations it is safe following brief suspensions that cast doubt on a vaccine that is critical to ending the coronavirus pandemic.